乌司奴单抗治疗克罗恩病口腔表现的病例报告
本病例报告描述一名12岁男孩以疼痛性、持续性、弥漫性口腔溃疡为首发表现,经诊断检查确诊为克罗恩病(CD)。经布地奈德、泼尼松和英夫利西单抗治疗后出现高滴度抗英夫利西单抗抗体且口腔病变控制不佳,换用乌司奴单抗后口腔和肠道表现均显著改善。建议牙科医生与消化科医生协作管理CD的口腔表现。
要点
- 克罗恩病可表现为牙龈炎、黏膜赘、阿弗他溃疡、唇肿胀、鹅卵石样改变和口腔前庭线状溃疡。
- 乌司奴单抗是抗p40抗体,抑制白介素12和23,通常用于抗TNF药物(如英夫利西单抗)失败后。
- 牙科医生与消化科医生协作管理克罗恩病口腔表现,可能改善患者预后和生活质量。
核心结论
- 乌司奴单抗治疗后,该青少年患者的克罗恩病口腔和肠道表现均显著改善。
- 牙科医生与消化科医生协作管理克罗恩病口腔表现,可能改善预后和生活质量。
研究设计与样本
- 病例报告:一名既往健康的12岁男孩,因疼痛性、持续性、弥漫性口腔溃疡就诊,诊断检查支持克罗恩病诊断。
主要发现
- 患者经布地奈德、泼尼松和英夫利西单抗输注治疗,后出现高滴度抗英夫利西单抗抗体且口腔病变控制不佳。
- 换用乌司奴单抗后,口腔和肠道表现均显著改善。
关键数值与推荐
- 克罗恩病口腔表现包括牙龈炎、黏膜赘、阿弗他溃疡、唇肿胀、鹅卵石样改变和口腔前庭线状溃疡。
- 乌司奴单抗是抗p40抗体,抑制白介素12和23,通常在抗TNF药物(如英夫利西单抗)失败后使用。
临床怎么用
- 牙科医生应认识克罗恩病的口腔表现,并与消化科医生协作管理。
- 对于抗TNF治疗失败且口腔病变控制不佳的克罗恩病患者,乌司奴单抗是可考虑的选择。
局限性
- 本文为单个病例报告,结论的外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The authors reviewed a case involving the orofacial manifestations of Crohn disease (CD) in an adolescent whose treatment was ultimately managed with a newer class of biologic drug agent, ustekinumab (Stelara, Janssen Biotech). CD is a chronic inflammatory condition affecting the gastrointestinal tract that often causes extraintestinal complications. The underlying etiology of CD involves genetic, environmental, and local factors. Orofacial manifestations of CD include gingivitis, mucosal tags, aphthous ulcerations, labial swellings, cobblestoning, and linear ulcers of the oral vestibules. CASE DESCRIPTION: A previously healthy 12-year-old boy presented with painful, constant, diffuse oral ulcerations. His diagnostic and laboratory testing supported a diagnosis of CD. The patient was then treated with budesonide (Entocort, Perrigo Company), prednisone (Deltasone, Pfizer Inc), and infliximab infusions (Remicade, Janssen Biotech). Later, he had high levels of anti-infliximab antibodies and inadequate control of his orofacial lesions. He then began taking a different class of biologic medication, ustekinumab. After initiation of ustekinumab, both his oral and intestinal manifestations markedly improved. PRACTICAL IMPLICATIONS: Collaboration between the treating dentist and treating gastroenterologist is recommended for management of the orofacial manifestations of CD. This may lead to an improvement in the patient's prognosis and quality of life. Ustekinumab is an anti-p40 antibody that inhibits interleukins 12 and 23. It is a newer biologic medication, and its use has been increasing in the pediatric population with CD. Its use is typical after failure of an antitumor necrosis factor drug, like infliximab.
引用
- Ruck P, Gosnell ES, Rick JR, et al. Oral manifestations of Crohn disease managed with ustekinumab: A case report. J Am Dent Assoc. 2024. PMID: 39692644. doi:10.1016/j.adaj.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。